Medicare AdvantageCoverageMedium impact
MA08.140c, Anifrolumab-fnia (Saphnelo®)
Independence Blue Cross·Rheumatology, Nephrology·Pharmacy
Effective date
May 28, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage policy MA08.140c for Anifrolumab-fnia (Saphnelo®) has been reissued with updates effective May 28, 2025. This is a pharmacy-related policy change that may affect coverage or authorization requirements for this specialty medication used to treat systemic lupus erythematosus.
Action Required
By May 28, 2025: Billing team should review the full policy details at the provided URL to understand specific changes to Anifrolumab-fnia (Saphnelo®) coverage requirements for Medicare Advantage patients. Update any prior authorization processes or coverage criteria as specified in the complete policy document.